Induced pluripotent stem cell technology: a decade of progress.
Level 5 - mechanism / opinion, no new human data
Narrative review summarizing historical progress and applications of iPSC technology.
PubMed 27980341 · doi:10.1038/nrd.2016.245
What was done
This narrative review summarizes progress made during the first decade of induced pluripotent stem cell (iPSC) technology, focusing on applications in stem cell biology, regenerative medicine, disease modeling, drug discovery, cell therapy, and integration with gene editing and 3D organoids.
What was found
The abstract describes broad technological and translational milestones rather than quantitative trial findings. It reports that novel pathological mechanisms have been identified, new drugs from iPSC screens are in development pipelines, and the first clinical trial using human iPSC-derived products has commenced. No numerical data or statistical comparisons are provided in the abstract.
Why it matters
The paper charts the translation of iPSC technology from basic stem cell biology into translational pipelines for drug discovery, precision medicine, and regenerative therapeutics.
Limits
This is a narrative review without systematic search methods or quantitative synthesis. As reported in the abstract, no primary experimental data, clinical sample sizes, efficacy statistics, or safety endpoints are provided.
Cited by
- supports Clinical trials in Japan have started using induced pluripotent stem cell technology derived from Yamanaka factors in human patients.